Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.59 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673191 | 1.00 | HCRTR1 (0.59) | HCRTR1HCRTR2GPR119HTR2CHTR2A | |
| SCHEMBL17519297 | 0.80 | NR1H2 (0.55) | HCRTR1HCRTR2GPR119NR1H2NR1H3 | |
| SCHEMBL24963646 | 0.77 | ACHE (0.59) | GPR119 | |
| SCHEMBL19218045 | 0.76 | NR1H3 (0.38) | HCRTR1HCRTR2GPR119NR1H2NR1H3 | |
| SCHEMBL1672836 | 0.76 | HCRTR1 (0.59) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL1672834 | 0.76 | HCRTR1 (0.59) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL27379938 | 0.75 | GPR119 (0.56) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL1671979 | 0.74 | HCRTR1 (0.62) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL1671980 | 0.74 | HCRTR1 (0.62) | HCRTR1HCRTR2GPR119 | |
| SCHEMBL1672065 | 0.74 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680275-B2 | Fused heterocyclic compounds as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| EP-2491034-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-18 | — | — | EP | disclosed |
| EP-2491034-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN RESEARCH NV (BE) | 2012-08-09 | — | — | US | disclosed |
| WO-2011050200-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202783-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885GPR119 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.